Advances in the development of a targeted N-Terminal Domain androgen receptor (AR) degrader (ANITAC) for the treatment of prostate cancer. (October 2022) - Hong, N.H.; Biannic, B.; Virsik, P.; Zhou, H.J.; Le Moigne, R.